Find out what WWARN and partners are doing at the ASTMH Annual Meeting.
Will you be attending this year’s American Society of Tropical Medicine and Hygiene 64th Annual Meeting? The WWARN team hopes to catch up with you to exchange ideas on how we might work together.
The WWARN team will have a meeting room space where we would be delighted to arrange a side meeting with you during the conference – please let us know in advance if you would like to meet us.
Highlights from WWARN and partner sessions:
- Tuesday 27 October, 8:00-9:45 ‘The Pandemic of Falsified and Substandard Medical Products: Detection Techniques and Policy Recommendations’
Location: Marriott - Grand Ballroom Salon H
This symposium, co-chaired by WWARN’s Director, Prof Philippe Guérin, will address the threat of substandard and falsified medical products, a serious threat to global public health, by exploring new technologies for identifying falsified medicines, field innovations for defining their prevalence, and the broader policy implications that require governments' attention. The speakers will also provide recommendations for model international regulations and a governing entity to take sustainable corrective action against those involved in the sale of poor quality medicines.
- Tuesday 27 October, 12:00-13:45 ‘Getting the lumefantrine dose right for the treatment of uncomplicated malaria; a pooled pharmacometric approach’
Location: Convention Center - 100AB
Former WWARN Postdoctoral Pharmacometrician, Frank Kloprogge, will present the results of his last year’s work with WWARN. Artemether-lumefantrine (ARM-LF) is the most widely used antimalarial treatment in the world. This poster presentation will outline his investigation into the population pharmacokinetic-pharmacodynamic (PK-PD) properties of LF using pooled data from paediatric, pregnant and adult patients from Africa, South East Asia and Oceania. In-silico dose optimisations, using the developed models, were used to evaluate the pharmacokinetic exposure of LF after prolonged treatment, intensified treatment and increased dosage for paediatric and pregnant patients when compared to adults, receiving the standard dosing regimen.
- Wednesday 28 October, 13:45-15:30 ‘Tracking Resistance to Artemisinin Collaboration II: Latest Findings from Clinical, Parasitological, and Molecular Studies’
Location: Marriott - Grand Ballroom Salon F
This symposium, led by partners from the National Institutes for Health and the Mahidol-Oxford Tropical Medicine Research Unit, will present the latest findings from the second stage of the Tracking Resistance to Artemisinin Collaboration project known as TRAC II. The presentations aim to better define artemisinin combination therapies in the context of the emergence and spread of resistance in Southeast Asia. These presentations will stimulate thoughtful discussions about the threat of ACT-resistant Plasmodium falciparum malaria, and the challenges of eliminating this disease from Southeast Asia.
If you’re not able to join us then why not follow what’s happening at the conference over Twitter by following us on @WWARN. Read our latest news or email info@wwarn.org with your questions.
Join us online and share your news from the conference:
- Tweet @WWARN using the #tropmed15 hashtag or visit twitter.com/WWARN
- ‘Like’ WWARN here www.facebook.com/AntimalarialResistance